Physician profile
Ruth Frank
NPI 1962622407
$1,760.61
in general payments reported to CMS, 2019-2025
24 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $144 · 2021: $328 · 2022: $158 · 2023: $137 · 2024: $488 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,010.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $222.80 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $202.79 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $164.23 | 2020-2024 | |
| Otsuka America Pharmaceutical, INC. | $150.06 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $132.79 | 2024-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $113.04 | 2020-2022 | |
| Axsome Therapeutics, INC. | $111.62 | 2024-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.74 | 2021-2025 | Caplyta |
| Collegium Pharmaceutical, INC. | $69.53 | 2025 | Jornay Pm |
| Indivior INC. | $65.77 | 2022-2025 | Sublocade |
| Harmony Biosciences LLC | $64.18 | 2020-2024 | Wakix |
| Eisai INC. | $50.68 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $42.35 | 2021 | |
| Sage Therapeutics, LLC | $41.13 | 2024-2025 | Zurzuvae |
| Lundbeck LLC | $40.27 | 2021-2023 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $37.81 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $31.50 | 2024 | Spravato |
| Corium, LLC | $21.00 | 2023 | Azstarys |
| Alkermes, INC. | $20.44 | 2023 | Lybalvi |
| Vertical Pharmaceuticals, LLC | $19.77 | 2025 | Relexxii |
| Teva Pharmaceuticals USA, INC. | $17.82 | 2024 | Austedo Xr |
| Supernus Pharmaceuticals, INC. | $17.80 | 2025 | Qelbree |
| Tris Pharma INC | $16.40 | 2023 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $16.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Frank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.